What's New: Drugs RSS Feed
- User Fee Lists November 26, 2021
- What's New Related to Drugs November 26, 2021
- Generic Drug Facilities, Sites and Organization Lists November 26, 2021
- Information on Clozapine November 26, 2021
- Completed Research Projects | Office of Prescription Drug Promotion (OPDP) Research November 26, 2021
- Competitive Generic Therapy Approvals November 26, 2021
- Drugs@FDA Data Files November 24, 2021
- FDA updates on hand sanitizers consumers should not use November 24, 2021
- Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee) Roster November 24, 2021
- P&G Issues Voluntary Recall of Specific Old Spice and Secret Aerosol Spray Antiperspirants and Old Spice Below Deck Aerosol Spray Products Due to Detection of Benzene November 24, 2021
What's new
- COVID-19: latest updates November 26, 2021
- Human medicines European public assessment report (EPAR): Insulin aspart Sanofi, insulin aspart, Diabetes Mellitus, Date of authorisation: 25/06/2020, Revision: 3, Status: Authorised November 26, 2021
- Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 06/01/2021, Revision: 16, Status: Authorised November 26, 2021
- Human medicines European public assessment report (EPAR): Comirnaty, Tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revision: 15, Status: Authorised November 26, 2021
- Human medicines European public assessment report (EPAR): Pemetrexed Lilly, pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 14/09/2015, Revision: 7, Status: Withdrawn November 26, 2021
- Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Peanut Hypersensitivity, Date of authorisation: 17/12/2020, Revision: 2, Status: Authorised November 26, 2021
- Human medicines European public assessment report (EPAR): Inbrija, levodopa, Parkinson Disease, Date of authorisation: 19/09/2019, Revision: 3, Status: Authorised November 26, 2021